TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
Opioid dependence remains a major driver of death and disease worldwide
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
The trial also demonstrated significant improvements across multiple secondary endpoints
The new capital is expected to fund the company through 2029
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
Analysis of over 93 lakh preventive health checkups reveals disease risks emerging as early as the 20s
Health of the Nation 2026, based on over 3 million assessments, finds rising diabetes, obesity, and hidden cardiac risks in under-30s and working professionals
Subscribe To Our Newsletter & Stay Updated
